Cancer name Breast Cancer
Cancer Type BRCA
Immunotherapy type Adoptive Cell Therapy
Treatment c-Met RNA CAR T cell
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature CD4+ T cells
Official Symbol CD4+ T helper cell
Mode of action CE_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental clinical trial phase 1
Description In addition, we compared the tissue effects of intratumoral injection of 1 mL of lidocaine (as negative control) and 1 mL of mRNA c-Met-CAR T cells in one patient and noted that intratumoral injection of mRNA c-Met-CAR T cells, not lidocaine, resulted in more immune cell infiltration. We noted that the T cells within the intratumoral injection site were predominantly CD4+ and that some of the infiltrated immune cells were CD68+ macrophages.
PMID 29109077
Title Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer